Recursion Pharmaceuticals (RXRX) TL;DR Synthesis
Leadership Transition & Governance Effective January 1, 2026, Dr. Najat Khan (current CRDO/CCO) will succeed co-founder Dr. Christopher Gibson as CEO and President, supporting the next growth phase focused on executing the Recursion OS platform. Dr. Gibson transitions to Chairman of the Board and Executive Advisor for 12 months; Robert Hershberg is Lead Independent Director. Dr. Khan’s compensation includes a \(680,000 base salary and immediate equity awards totaling \)1 million, with potential for an additional $7.5 million award.
**Fin
...